K. H. Kim (1), W. S. Choi (1), J. H. Lee (1), H. Lee (2), D. H. Yang (1), S. C. Chae (1)
(1) Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea; (2) Department of Public Health, Kyungpook National University, Daegu, Republic of Korea
Little study has been performed on the effect of vitamin K intake on the variability of warfarin’s anticoagulant effects over long period of time. We estimated average vitamin K intake in the patients taking warfarin and evaluated its relation with the stability of anticoagulation effect. We estimated average daily vitamin K intake based on a three-day food diary in 66 patients taking warfarin regularly for ≥ one year and divided them into three groups of equal number according to vitamin K intake. Stability of anticoagulant effect was compared in these groups using the coefficient of variation (CV) of the prothrombin time expressed in international normalised ratio (INR) and the CV of warfarin doses. Median daily vitamin K intake was 161.3 μg/day (31.3 μg/day – 616.6 μg/day). CVs of both INR and warfarin doses were negatively and independently correlated with dietary vitamin K intake (r=-0.293, p=0.017 and r= –0.350, p=0.004, respectively). CV of INR was significantly different among three groups of vitamin K intake (p<0.05 in ANOVA). High vitamin K intake (>195.7 μg/day) group had lower CV of INR than the low intake (<126.5 μg/day) group (19.2 ± 8.96 % vs. 25.5 ± 8.61 %, p<0.05). CV of warfarin doses was also significantly different among the groups (p<0.05 in Jonckheere-Terpstra test). However, the significance of difference between high and low vitamin intake groups was marginal (p=0.046 in Mann-Whitney test). In conclusion, long-term anticoagulation effect of warfarin is more stable in the patients who take greater than a certain amount of dietary vitamin K.
stability, oral anticoagulant, vitamin K
S. Seifert1, C. Jentschel1, R. Bergmann1, H.-J. Pietzsch1, G. Wunderlich2, J. Kotzerke2, J. Steinbach1
Nuklearmedizin 2007 46 5: 181-184
Pablo García de Frutos1, Pablo Fuentes-Prior2, Begoña Hurtado3, Núria Sala3
Thromb Haemost 2007 98 3: 543-556
Matthias Watzka1,2*, Almut Nebel3*, Nour Eddine El Mokhtari4, Boris Ivandic5, Jens Müller1, Stefan Schreiber3, Johannes Oldenburg1
Thromb Haemost 2007 97 6: 998-1002
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...